ProCE Banner Series

Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists

Join us in person or virtually for this 1-hour, CPE-certified symposium at HOPA AC24, where pharmacist experts will discuss current and emerging regimens leveraging ADCs directed against HER2, HER3, and TROP-2. Get up to date on how oncology pharmacists can optimize care for patients receiving ADCs, from patient education to toxicity identification and management.

Please note: You must be registered for the HOPA 2024 Conference to attend this symposium in person. You may register at: https://hopa2024.eventscribe.net/index.asp

  ACPE-P
Who Should Attend

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with solid tumor cancers.

All Events

Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists

Past Events

April

05

2024

7:00 AM - 8:00 AM Eastern Time (ET)

In-personVirtual

Tampa Convention Center, 333 S Franklin St., Tampa, Florida 33602

Faculty

ProCE Banner Faculty
Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky

ProCE Banner Faculty
Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in identifying and managing adverse events associated with antibody–drug conjugate therapies in solid tumor cancers. 

Target Audience
This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with solid tumor cancers. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Analyze clinical evidence supporting the use of ADCs targeting HER2, HER3, and TROP-2
  • Explain the structural, mechanistic, and unique characteristics of ADCs that contribute to differing toxicities and adverse event profiles
  • Identify strategies for managing common and serious toxicities to effectively monitor and proactively identify signs and symptoms of serious adverse events
  • Develop strategies to manage common and serious toxicities or adverse events associated with approved and emerging antibody–drug conjugate therapies
  • Apply knowledge of ADCs, clinical evidence, and guidelines to real-world patient case scenarios

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-24-001-L01-P has been assigned to this live application-based activity (initial release date 1/10/2024). This activity is approved for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.